Predictive Oncology (NASDAQ: POAI) Releases Third-Quarter 2020 Business Update, Financial Report
Financial numbers show revenues stay level, gross margins up and operations expenses down. Company continues focus on primary mission of applying artificial intelligence to precision medicine, drug discovery. POAI subsidiaries all showing progress, growth in key areas. Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released its Q3 2020 financial report along with an update of company accomplishments and achievements (https://nnw.fm/kqPOl). In the report, POAI CEO Dr. Carl Schwartz noted milestones for each of the company’s subsidiaries: Helomics, TumorGenesis, Soluble Biotech and Skyline Medical. “Our operating cash improved over…